← Back to Search

EGFR Inhibitor

EGFR Inhibitor for Non-Small Cell Lung Cancer

Phase 1 & 2
Waitlist Available
Led By Pasi Antero Janne, M.D & Ph. D
Research Sponsored by Dizal Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
In the past 6 months, have you not had a stroke or brain bleed?
Do you not have a history of pulmonary fibrosis/pneumonitis/interstitial lung disease?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through the study completion, an average of around 1 year
Awards & highlights

Study Summary

This trial will test a new drug on patients with advanced lung cancer who have progressed after other treatments. It will help to understand side effects and how well the drug works on its own.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through the study completion, an average of around 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through the study completion, an average of around 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part A: Safety and tolerability of DZD9008.
Part B: Objective Response Rate (ORR) according to RECIST 1.1.
Secondary outcome measures
Plasma DZD9008 concentration

Trial Design

8Treatment groups
Experimental Treatment
Group I: Part B Dose extension (Ongoing)Experimental Treatment1 Intervention
Patients with EGFR Exon20ins should have received at least 1 line, but no more than 3 lines of systemic therapy for metastatic/locally advanced disease.
Group II: Part A Dose expansion cohort 6Experimental Treatment1 Intervention
Group III: Part A Dose expansion cohort 5 (Ongoing)Experimental Treatment1 Intervention
Patients with EGFR Exon20ins, treatment naïve
Group IV: Part A Dose expansion cohort 4 (Ongoing)Experimental Treatment1 Intervention
Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
Group V: Part A Dose expansion cohort 3Experimental Treatment1 Intervention
Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
Group VI: Part A Dose expansion cohort 2Experimental Treatment1 Intervention
Group VII: Part A Dose expansion cohort 1Experimental Treatment1 Intervention
Group VIII: Part A Dose escalationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DZD9008
2021
Completed Phase 1
~80

Find a Location

Who is running the clinical trial?

Dizal PharmaceuticalsLead Sponsor
20 Previous Clinical Trials
1,713 Total Patients Enrolled
Pasi Antero Janne, M.D & Ph. DPrincipal InvestigatorDana-Farber Cancer Institute

Media Library

DZD9008 (EGFR Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03974022 — Phase 1 & 2
Non-Small Cell Lung Cancer Research Study Groups: Part A Dose expansion cohort 5 (Ongoing), Part A Dose expansion cohort 6, Part B Dose extension (Ongoing), Part A Dose expansion cohort 1, Part A Dose expansion cohort 2, Part A Dose expansion cohort 3, Part A Dose expansion cohort 4 (Ongoing), Part A Dose escalation
Non-Small Cell Lung Cancer Clinical Trial 2023: DZD9008 Highlights & Side Effects. Trial Name: NCT03974022 — Phase 1 & 2
DZD9008 (EGFR Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03974022 — Phase 1 & 2
Non-Small Cell Lung Cancer Patient Testimony for trial: Trial Name: NCT03974022 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants may join this research project?

"Affirmative. The information on clinicaltrials.gov indicates that this research is currently enrolling participants, having been initially posted on July 9th 2019 and last updated September 21st 2022. Eleven different medical sites are recruiting a total of 336 patients for the trial."

Answered by AI

Is the window for enrollment in this trial still open?

"Per the data on clinicaltrials.gov, this research is still recruiting patients. It was initially posted in July 9th 2019 and modified most recently on September 21st 2022."

Answered by AI

Are there numerous sites in the state conducting this clinical experiment?

"This clinical trial is being held at 11 distinct sites, including Northwell Health - Centers for Advanced Medicine in New Hyde Park, Michigan Center of Medical Research in Farmington Hills, and H. Lee Moffitt Cancer Center & Research Institute in Tampa."

Answered by AI

Who else is applying?

What state do they live in?
Ohio
California
Florida
Other
What site did they apply to?
Innovative Clinical Research Institute, LLC
Michigan Center of Medical Research
H. Lee Moffitt Cancer Center & Research Institute
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
2
3+
0
1

Why did patients apply to this trial?

Because I have emphasism. I'm reviewing all options. Brian Old Street Health Clinic.
PatientReceived 1 prior treatment
Anything that can help... Simple! Odepo keytruda at least 8 different chemos.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

Is this chemotherapy? How long does visit take?
PatientReceived no prior treatments

How responsive is this trial?

Average response time
  • < 2 Days
Most responsive sites:
  1. Michigan Center of Medical Research: < 48 hours
  2. H. Lee Moffitt Cancer Center & Research Institute: < 48 hours
  3. University of California, San Diego (UCSD) - Moores Cancer Center: < 48 hours
Typically responds via
Phone Call
Recent research and studies
clinicaltrials.govStudy
Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
2019. "Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03974022.
~58 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top